Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria - A double-center prospective study

Journal of Infectious Diseases

Volumn 209, Issue 12, 2014, Pages 1921-1928

  Rolling, Thierry ^a,b,c   Agbenyega, Tsiri ^d   Issifou, Saadou ^c,e   Adegnika, Ayola Akim ^c,e   Sylverken, Justice ^d,f   Spahlinger, Dorothee ^a,b   Ansong, Daniel ^d,f   Löhr, Sascha J Z ^c,e   Burchard, Gerd D ^a,b   May, Jürgen ^b   Mordmüller, Benjamin ^c,e   Krishna, Sanjeev ^c,e,g   Kremsner, Peter G ^c,e   Cramer, Jakob P ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c Centre de Recherches Médicales de Lambaréné HÔpital Albert Schweitzer   (Gabon)

^d KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

adverse events; African children; artesunate; hemolysis; Severe malaria

Indexed keywords

ARTESUNATE; HEMOGLOBIN; LACTATE DEHYDROGENASE;

AFRICAN; AGE; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GEOMETRIC MEAN PARASITE DENSITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYTIC ANEMIA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; MICROBIOLOGICAL PARAMETERS; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SICKLE CELL;

ADVERSE EVENTS; AFRICAN CHILDREN; ARTESUNATE; HEMOLYSIS; SEVERE MALARIA;

ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GABON; GHANA; HEMOLYSIS; HUMANS; INFANT; MALARIA; MALE; PROSPECTIVE STUDIES;

EID: 84901810078     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit841     Document Type: Article

References (33)

1. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010:a systematic analysis. Lancet 2012; 379:413-31.
2. World Health Organization (WHO). World malaria report: 2012. Geneva, 2012.
3. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717-25. (Pubitemid 41207233)
4. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647-57.
5. Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2012; 6:CD005967.
6. World Health Organization (WHO). Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland, 2010.
7. Cramer JP, Lopez-Velez R, Burchard GD, Grobusch MP, de Vries PJ. Treatment of imported severe malaria with artesunate instead of quinine-more evidence needed? Malar J 2011; 10:256.
8. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J 2012; 11:102.
9. Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard GD, Cramer JP. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J 2012; 11:169.
10. Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011; 17:771-7.
11. Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J 2013; 12:241.
12. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2013.
13. Afrane YA, Klinkenberg E, Drechsel P, Owusu-Daaku K, Garms R, Kruppa T. Does irrigated urban agriculture influence the transmission of malaria in the city of Kumasi, Ghana? Acta Trop 2004; 89:125-34. (Pubitemid 38056634)
14. Sylla EH, Kun JF, Kremsner PG. Mosquito distribution and entomological inoculation rates in three malaria-endemic areas in Gabon. Trans R Soc Trop Med Hyg 2000; 94:652-6.
15. Taylor T, Olola C, Valim C, et al. Standardized data collection for multicenter clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg 2006; 100:615-22.
16. Kremsner PG, Taylor T, Issifou S, et al. A simplified intravenous artesunate regimen for severe malaria. J Infect Dis 2012; 205:312-9.
17. Kremsner PG, Valim C, Missinou MA, et al. Prognostic value of circulating pigmented cells in African children with malaria. J Infect Dis 2009; 199:142-50.
18. Riley RS, Ben-Ezra JM, Goel R, Tidwell A. Reticulocytes and reticulocyte enumeration. J Clin Lab Anal 2001; 15:267-94. (Pubitemid 32896024)
19. Kreuels B, Kreuzberg C, Kobbe R, et al. Differing effects of HbS and HbC traits on uncomplicated falciparum malaria, anemia, and child growth. Blood 2010; 115:4551-8.
20. May J, Meyer CG, Grossterlinden L, et al. Red cell glucose-6-phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population. Trop Med Int Health 2000; 5:119-23. (Pubitemid 30159129)
21. Chau TTH, Day NPJ, Van Chuong L, et al. Blackwater Fever in Southern Vietnam: A Prospective Descriptive Study of 50 Cases. Clin Infect Dis 1996; 23:1274-81. (Pubitemid 26423165)
22. Van den Ende J, Coppens G, Verstraeten T, et al. Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health 1998; 3:632-9. (Pubitemid 28394592)
23. Nealon C, Dzeing A, Muller-Romer U, et al. Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother 2002; 46:3933-9. (Pubitemid 35403271)
24. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 2011; 10:263.
25. Schnitzer B, Sodeman T, Mead ML, Contacos PG. Pitting Function of the Spleen in Malaria: Ultrastructural Observations. Science 1972; 177:175-7.
26. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 1997; 90:2037-40. (Pubitemid 27377317)
27. Chotivanich K, Udomsangpetch R, Dondorp A, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis 2000; 182:629-33. (Pubitemid 30651065)
28. Silvergleid A. Immunologic blood transfusion reactions. In: Basow D, ed. UpToDate. Waltham, MA: UpToDate, 2013.
29. Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy? Bull World Health Organ 2011; 89:838-45.
30. Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol 2011; 7:1185-200.
31. Corpolongo A, De Nardo P, Ghirga P, et al. Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine. Malar J 2012; 11:91.
32. Merat S, Lambert E, Vincenti-Rouquette I, Gidenne S, Rousseau JM, Brinquin L. Case report: combination artemether-lumefantrine and haemolytic anaemia following a malarial attack. Trans R Soc Trop Med Hyg 2003; 97:433-4. (Pubitemid 39186026)
33. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341:603-8. (Pubitemid 23066156)